<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="publisher-id">ci</journal-id>
    <journal-id journal-id-type="coden">jcisd8</journal-id>
    <journal-title-group>
      <journal-title>Journal of Chemical Information and Modeling</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1549-9596</issn>
    <issn pub-type="epub">1549-960X</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9930109</article-id>
    <article-id pub-id-type="pmid">36728505</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jcim.2c01191</article-id>
    <article-categories>
      <subj-group>
        <subject>Application Note</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Chemistry42: An
AI-Driven Platform for Molecular Design
and Optimization</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8968-0879</contrib-id>
        <name>
          <surname>Ivanenkov</surname>
          <given-names>Yan A.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0899-8368</contrib-id>
        <name>
          <surname>Polykovskiy</surname>
          <given-names>Daniil</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <name>
          <surname>Bezrukov</surname>
          <given-names>Dmitry</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <name>
          <surname>Zagribelnyy</surname>
          <given-names>Bogdan</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">§</xref>
      </contrib>
      <contrib contrib-type="author" id="ath5">
        <name>
          <surname>Aladinskiy</surname>
          <given-names>Vladimir</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">§</xref>
      </contrib>
      <contrib contrib-type="author" id="ath6">
        <name>
          <surname>Kamya</surname>
          <given-names>Petrina</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath7">
        <name>
          <surname>Aliper</surname>
          <given-names>Alex</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">§</xref>
      </contrib>
      <contrib contrib-type="author" id="ath8">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9157-9182</contrib-id>
        <name>
          <surname>Ren</surname>
          <given-names>Feng</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">∥</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath9">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7067-8966</contrib-id>
        <name>
          <surname>Zhavoronkov</surname>
          <given-names>Alex</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label><institution>Insilico
Medicine Kong Kong Ltd.</institution>, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, <country>Hong Kong</country></aff>
      <aff id="aff2"><label>‡</label><institution>Insilico
Medicine Canada Inc.</institution>, 3710-1250 René-Lévesque Blvd W, Montreal, Quebec, H3B
4W8 <country>Canada</country></aff>
      <aff id="aff3"><label>§</label><institution>Insilico
Medicine AI Limited</institution>, Level 6, Unit 08, Block A, IRENA HQ Building, Masdar City, PO Box 145748, Abu Dhabi, <country>UAE</country></aff>
      <aff id="aff4"><label>∥</label><institution>Insilico
Medicine Shanghai Ltd.</institution>, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, <country>China</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>alex@insilico.com</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>02</day>
      <month>02</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>13</day>
      <month>02</month>
      <year>2023</year>
    </pub-date>
    <volume>63</volume>
    <issue>3</issue>
    <fpage>695</fpage>
    <lpage>701</lpage>
    <history>
      <date date-type="received">
        <day>22</day>
        <month>09</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci2c01191_0005" id="ab-tgr1"/>
      </p>
      <p>Chemistry42 is a software platform for <italic>de novo</italic> small molecule design and optimization that integrates Artificial
Intelligence (AI) techniques with computational and medicinal chemistry
methodologies. Chemistry42 efficiently generates novel molecular structures
with optimized properties validated in both <italic>in vitro</italic> and <italic>in vivo</italic> studies and is available through licensing
or collaboration. Chemistry42 is the core component of Insilico Medicine’s <bold>Pharma.ai</bold> drug discovery suite. Pharma.ai also includes PandaOmics
for target discovery and multiomics data analysis, and inClinico—a
data-driven multimodal forecast of a clinical trial’s probability
of success (PoS). In this paper, we demonstrate how the platform can
be used to efficiently find novel molecular structures against DDR1
and CDK20.</p>
    </abstract>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ci2c01191</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ci2c01191</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Deep Learning (DL) has proven to be very
effective in speech and
image recognition. This is because DL-based architectures are uniquely
suited for the automatic identification of patterns within complex,
nonlinear data sets without the need for manual feature engineering.
DL methods have recently been adapted to successfully overcome limitations
inherent in the standard techniques used for small molecule design.<sup><xref ref-type="bibr" rid="ref1">1</xref>−<xref ref-type="bibr" rid="ref3">3</xref></sup> These adaptations offer exciting possibilities for the development
of new methods that efficiently explore uncharted chemical space.</p>
    <p>Insilico Medicine was one of the first groups to publish a method
that uses a deep adversarial model for new compound generation.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Since then, DL-based architectures that combine
generative algorithms with reinforcement learning (RL) have been developed
and applied in chemistry and pharmacology to generate novel molecular
structures with predefined properties.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Especially encouraging is the recent progress in the <italic>de
novo</italic> design of active molecules that have been validated
in both <italic>in vitro</italic> and <italic>in vivo</italic> assays.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref6">6</xref></sup> Generative chemistry is now one of the fastest-growing areas in
drug discovery.<sup><xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref8">8</xref></sup> The
Chemistry42 platform has been routinely and successfully used at Insilico
Medicine to drive the drug discovery process in several therapeutic
areas (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://insilico.com/pipeline">https://insilico.com/pipeline</uri>) and has evolved significantly during the past years.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> In the following sections, we describe the key
features of the Chemistry42 platform.</p>
  </sec>
  <sec id="sec2">
    <title>Overview of the Generative Capabilities of the Chemistry42 Platform</title>
    <p>Chemistry42 is a platform that connects state-of-the-art generative
AI algorithms with medicinal and computational chemistry expertise
and best engineering practices. It was launched in 2020 and has been
used by over 20 pharmaceutical companies, over 15 external programs,
and over 30 internal programs.</p>
    <p>The main objective of this platform
is to accelerate the design
of novel molecules with user-defined properties. The general workflow
for Chemistry42 is illustrated and described in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>.</p>
    <fig id="fig1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>A schematic representation of the three-step
workflow for a <italic>de novo</italic> generative experiment using
the Chemistry42 platform.
In the first step, on a secure and company-specific instance of the
software, users upload their data and configure the platform with
the desired properties for the generated structures. The second step
involves running the platform where an ensemble of 40+ generative
models functions in parallel to generate the novel structures—this
step is called the generation phase. A variety of filters scrutinize
the generated molecular structures in the generation phase. The molecular
structures are then subjected to multiple sets of reward and scoring
modules, classified as either 2D or 3D modules, that dynamically assess
the generated structures’ properties according to the predefined
criteria. Additional custom scoring modules (such as ADME predictors)
can also be integrated into the reward pipeline to prioritize the
generated structures. These modules form the backbone of Chemistry42’s
multiagent reinforcement learning (RL)-based generation protocol.
Generated structures’ scores are fed back to the generative
models to reinforce them and guide the generative process toward high-scoring
structures—this is called the learning phase. The final step
is analysis. The generated structures are automatically ranked according
to customizable metrics based on their predicted properties, including
synthetic accessibility, novelty, diversity, etc. The platform also
provides users with interactive tools to monitor generative model
performance.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci2c01191_0001" id="gr1" position="float"/>
    </fig>
    <p>Generative experiments are created using the user-friendly
web-based
interface of Chemistry42 and can be started using ligand- or structure-based
drug design workflows depending on the available information for the
target of choice. The Ligand-Based Drug Design (LBDD) approach requires
a 2D or 3D ligand structure as input in an .sdf file, a SMILES string,
or the molecule can be sketched directly on the platform using the
handy sketcher panel. A pharmacophore hypothesis can also be added
as needed and created manually using a widget or automatically within
the platform. In the Structure-Based Drug Design (SBDD) approach,
the structure of a protein target, either in the <italic>apo</italic> format or in complex with a ligand, must be uploaded to the platform
as a prepared .pdb file. One can pick either the pocket around the
ligand (ligand binding site) or select one from the set of alternative
pockets indicated by the <italic>Pocket Scanner Module</italic>. As
with the case of LBDD, a pharmacophore hypothesis can also be added
as needed (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). To complete the configuration of a generation experiment, the
user defines acceptable ranges for multiple properties (e.g., physicochemical
properties and diversity) of the generated structures. The user can
prioritize reward modules by adjusting their weights and specify how
restrictive the modules should be by adjusting corresponding thresholds.
In both LBDD and SBDD approaches, advanced options enable the user
to specify and fine-tune reward modules and which generative models
should be used in an experiment. Hit expansion, hit-optimization,
and Fragment-Based Drug Design (FBDD) workflows are also available
on the platform through functionality called <italic>Anchor points.</italic> With <italic>Anchor points</italic>, users can fix in 3D space specified
cores or R-groups of a hit-molecule while the rest of the molecule
varies during a generative experiment. <italic>Anchor points</italic> also support multiple reference substructures by editing atom types
to include alternatives (supported by SMARTS). For example, the user
can specify whether they would like to see nitrogen or carbon in an
aromatic ring. Autoconfiguration is a quick way of adjusting all the
parameters automatically, based on the provided input data. To see
how the platform can be autoconfigured based on the input ligand structure
and properties see S1 section in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.2c01191/suppl_file/ci2c01191_si_001.pdf">SI</ext-link>.</p>
    <fig id="fig2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Chemistry42 interface for configuring an SBDD generative experiment.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci2c01191_0002" id="gr2" position="float"/>
    </fig>
    <p>The generative pipeline in Chemistry42 engages
an asynchronous
ensemble of proprietary generative models. These carefully curated
and selected algorithms have diverse architectures that implement
distinct strategies. The platform takes advantage of multiple machine
learning models and molecular representations for different generative
scenarios to maximize each model’s contribution and the platform’s
efficiency. For example, some models focus on the exploration of the
chemical space, while being tailored to improve these explored structures.
In the current version of Chemistry42, there are over 40 generative
models, including generative autoencoders,<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup> generative
adversarial networks,<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> flow-based approaches,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> evolutionary
algorithms,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> language models,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> and others. These models employ different molecular
representations—string-based, graph-based, and 3D-based.</p>
    <p>It is essential to understand and stimulate the interplay of multiple
generative models. As such, rather than treating these algorithms
as black-box solutions, we provide deep domain-specific analytics
to understand the advantages and drawbacks of each approach. Combining
various state-of-the-art machine learning methods, Chemistry42 delivers
diverse, high-quality molecular structures within hours. As the structures
are generated, they are dynamically assessed using the reward and
scoring modules in the platform.</p>
    <p>The reward and scoring modules
used in Chemistry42 for RL-based
generations are either two-dimensional (2D) or three-dimensional (3D)
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). The 2D
modules are composed of multiple scores and in-house <italic>Medicinal
Chemistry Filters</italic> (<italic>MCFs</italic>) that are used to
assess the generated structures. In the current version of Chemistry42,
the <italic>MCFs</italic> include a set of over 460 in-house structure-based
rules that exclude “bad” structures, i.e., those that
contain structure alerts, PAINS<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> or functional
groups that are reactive, unstable or potentially toxic. The <italic>Medicinal Chemistry Evolution</italic> (MCE-18) function is a unique
molecular descriptor that scores structures by novelty in terms of
their cumulative sp<sup>3</sup> complexity.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Other 2D modules include Lipinski’s Rule of Five (Ro5),<sup><xref ref-type="bibr" rid="ref18">18</xref></sup><italic>Drug-likeness</italic> and <italic>Weighted
atom-type portion descriptors</italic>, a rule-based filter that constitutes
a set of rules to eliminate structures with an unbalanced number of
heteroatoms and aromatic atoms. <italic>Novelty</italic> scores assess
the 2D similarity between the generated structures and the reference
data set (that can be customized) to improve novelty. <italic>Drug-likeness</italic> is estimated using a set of extended rules. The synthetic accessibility
(SA) of the generated structures is assessed using the <italic>Retrosynthesis
Related Synthetic Accessibility</italic> (ReRSA) score.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> ReRSA is an improved fragment-based SA estimation
method that is based on the fragmentation of the generated structure
from a retrosynthesis perspective, which results in a more accurate
estimation of SA. ReRSA also takes into account the space of commercially
available building blocks and rewards a structure if it can be converted
into existing building blocks (BBs). By default, ReRSA exploits the
approximately 200,000 commonly used BBs. <italic>Diversity</italic> assessments and clustering metrics are performed for the generated
structures using a custom similarity function. Tracking the <italic>Diversity</italic> of the generated structures provides a means of
understanding how structurally diverse the generated molecules are
based on the number of generated chemotypes following clustering. <italic>Privileged Fragments</italic> (PFs) are defined structural motifs
that contribute to the activity of a target or target class.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> PFs functionality is most useful in two types
of generative design workflows. The first involves defining 2D PF
substructure(s) that will be found in all generated structures with
no predefined positioning in 3D space. This is useful if you only
have an apoprotein structure with no reported inhibitors. For example,
if your target is the apo structures of the novel kinase, 2D PFs of
hinge binders can be used in the generative experiments to navigate
the generation into well-established chemical space. The second workflow
involves the use of <italic>Anchor Points</italic>—essentially
3D privileged fragments. Here, the presence of the substructure of
interest is essential in either a protein–ligand complex (SBDD
mode) or a 3D conformation of a ligand (LBDD mode). The self-organizing
maps (<italic>SOM) Classifier Module</italic> (general SOM map 100
× 100) is used to drive the generation of molecular structures
toward the chemical space corresponding to a specified target class.
Since the general SOM contains neurons with the classification power
below a predefined threshold for a selected category of molecules,
all the reference molecules from such neurons are collected and then
subjected to automatically generated ZOOM maps of an adapted size
to achieve reliable classification accuracy. The data set used to
train the SOMs <italic>Classifier Module</italic>,<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> and ZOOM maps are called the <italic>Hierarchical Active
Molecules</italic> (<italic>HAM)</italic> data set. The HAM data set
consists of data from 800k+ experimentally validated molecules with
IC50s of 10 μM or less. The Structure Morphing module contains
two components: a rule-based <italic>Metabolic Stability Enhancer</italic>(<xref ref-type="bibr" rid="ref22">22</xref>) that addresses metabolic instability
caused by potential sites of metabolism in the generated structures
and the <italic>Bioisostere Module</italic> that performs bioisosteric/isosteric
transformations.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></p>
    <p>Following the
assessment of the generated structures with the 2D
modules, multiple 3D modules are deployed for further assessment.
The <italic>ConfGen Module</italic> is the first 3D module. It produces
a conformational ensemble for each generated structure. The <italic>ConfGen Module</italic> generates conformational ensembles through
an in-house set of rules and predefined substructure geometries based
on small molecule cocrystal X-ray data followed by energy minimization
using Insilico’s proprietary force field. A flexibility assessment
(<italic>FLEX score</italic>) is used to rank molecular structures
by intrinsic rigidity. Once the conformational ensembles have been
generated, the <italic>3D-Descriptors Module</italic> evaluates the
3D similarity between the generated structures and a reference molecule
(input ligand) using a set of calculated 3D-descriptors. The <italic>Pharmacophore Module</italic> then assesses if any of the generated
conformations match the specified pharmacophore hypothesis, including
all important binding points, distances, angles, and tolerance. If
the <italic>Anchor Points</italic> module is used in the generation,
it checks if the user-defined 3D substructures are present in the
generated structure in the correct position and conformation. The <italic>Shape Similarity Module</italic> evaluates the 3D-shape similarity
to a reference molecule using weighted Gaussian functions.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> The final module focuses on positioning and
scoring the generated structures to assess how well they fit the selected
binding site (<italic>Pocket Module</italic>) and approximates the
binding affinity with a Pocket-Ligand Interaction (<italic>PLI</italic>) score. The <italic>PLI</italic> score was trained on the PDBBind
Refined Set v2020 (both <italic>K</italic><sub>i</sub> and <italic>K</italic><sub>d</sub> data were used).<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> The score takes into account hydrogen bonds, π-staking, π-cation,
XH-π, hydrophobic interactions, as well as salt bridges and
chelating bonds. The units of the <italic>PLI score</italic> are kcal/mol,
where the more negative the value, the better the score. The list
of most important scores and rewards for each individual workflow
(e.g., <italic>de novo</italic> SBDD or FBDD) is available in the
S2 section of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.2c01191/suppl_file/ci2c01191_si_001.pdf">SI</ext-link>. The tabulated list of
all mentioned modules, scores, and rewards, as well as default ranges,
values, and options, for them can be found in the S3 section of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.2c01191/suppl_file/ci2c01191_si_001.pdf">SI</ext-link>.</p>
    <p>The user can specify how long they
want to run the generative experiment.
In most cases, we observe convergence after 72 h. During a generative
experiment, the performance of each generative model is monitored
and recorded. This allows the user to follow the progress of their
experiments in real-time from start to completion. An example of the
generation monitoring at the early stage and after the completion
can be found in S4 section of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.2c01191/suppl_file/ci2c01191_si_001.pdf">SI</ext-link>. The generated
structures are automatically evaluated and ranked according to metrics
incorporated in the modules that are integrated into the platform.
All corresponding data, including scores, molecular structures, and
generative model performance, are stored and accessible on the results
page of the platform. Once a generative experiment is complete, the
results can be analyzed through an interactive interface.</p>
    <p>A
mediocre user can get valuable results (1–5 novel molecules
for synthesis) even from the first run of the generation for both
SBDD, LBDD, and other various workflows. The obtained results and
their subsequent analysis can help to configure the second run in
a more specific way to get more expected results. Usually, at the
second run the user can utilize some ideas that have been provided
by the platform at the first run (e.g., add some privileged structures
at the second run). An advanced user who is deeply familiar with the
functionality and outcomes of the platform can configure the platform
and get expected results (10–20 of novel molecules for synthesis)
even in the first run for a new project.</p>
    <p>A user is provided
at the platform with an online well-documented
manual describing sample virtual case studies for different workflows
mentioned in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.2c01191/suppl_file/ci2c01191_si_001.pdf">SI</ext-link> section S2, step-by-step
instructions for these case studies and sample outcomes as .sdf files
and their analysis by medicinal and computational chemists. These
case studies can help a fresher to accept the more appropriate strategy
to exploit the platform for their own project purposes.</p>
  </sec>
  <sec id="sec3">
    <title>Benchmarking the Generative Models in Chemistry42</title>
    <p>The
performance of all generative models used in an experiment
is monitored and recorded by a benchmarking system based on the Molecular
Sets (MOSES) system. MOSES assesses the performance of each model
and the reward components, including novelty, diversity, and others,
during the generation and once the experiment is completed.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Based on the provided analytics, users can analyze
each model’s performance. A record of the results and training
data is kept during the experiment and stored to ensure that reproducibility
and monitoring are both simple and feasible. An example of MOSES-based
analytics for a generation is available in the S5 of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.2c01191/suppl_file/ci2c01191_si_001.pdf">Supporting Information</ext-link>.</p>
  </sec>
  <sec id="sec4">
    <title>Case Studies</title>
    <p>Early versions of the generative pipeline
(prior to the launch
of Chemistry42), were used to demonstrate the ability of generative
algorithms to design experimentally validated, druglike molecular
structures (see <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p>
    <fig id="fig3" position="float">
      <label>Figure 3</label>
      <caption>
        <p>DDR1 inhibitors generation was performed in 2018 by the GENTRL
model in Case study 1 (above). The supporting postgeneration modules
(MCFs, SOMs, and pharmacophores) were utilized to narrow down the
generation output. Chemistry42 is an integrated platform released
in 2020, where more than 40 generative models work together and get
information from the reward modules and filters to produce molecular
structures with desired properties. The newer version of the platform
enables the exploitation of .pdb files of protein–ligand complexes
and apo-structures as input data. The CDK20 model from AlfaFold2 was
used in two sequential rounds of generation. The first round was focused
on the <italic>de novo</italic> design of potential CDK20 inhibitors
from apo-structure, while the second round exploited a hit-opt workflow
starting from the primary hit identified in the first round.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci2c01191_0003" id="gr3" position="float"/>
    </fig>
    <sec id="sec5">
      <title>Case Study 1: GENTRL Model Enabled the Rapid Generation of Potent
DDR1 Inhibitors</title>
      <p>The GENTRL model and postgeneration protocols
are the ancestors of the current architecture of the Chemistry42 platform.
In the seminal and widely discussed study<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> the model developed in 2018 generated experimentally validated potent
DDR1 kinase inhibitors. GENTRL was trained on the ZINC data set and
then fine-tuned on reported DDR1 inhibitors and a publicly available
kinase inhibitor data set. The obtained structures were then passed
through structural filters to eliminate structures with reactive groups,
PAINS, and other alerts. This functionality was further converted
into the <italic>MCFs</italic> module of the Chemistry42 platform.
The number of structures was further reduced by clustering and the
selection of the most diverse members of each cluster. This smaller
subset of structures was then assessed on kinase SOMs and by pharmacophore
hypotheses, constructed from reported cocrystals of DDR1 with its
inhibitors. The remaining structures were subject to a random selection
of 40 that were further subjected to a manual synthetic accessibility
evaluation. Of the 40 structures, six were nominated for synthesis
and biological assessment. By day 35, the compounds had been successfully
synthesized and tested <italic>in vitro</italic> for the inhibition
of DDR1 enzymatic kinase assay. More than half of the compounds were
found to be active (IC<sub>50</sub> &lt; 1 μM), including two
two-digit nanomolar inhibitors (10 nM and 21 nM), while two compounds
showed no activity in the assay.</p>
    </sec>
    <sec id="sec6">
      <title>Case Study 2: The Use of AlphaFold2 Generated 3D Protein Structures
to Generate Hit-Molecules</title>
      <p>We have recently demonstrated the
use of an AlphaFold2<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> predicted protein
structure in an SBDD case study of Cyclin-Dependent Kinase 20 (CDK20)
inhibitors.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> The selected target, CDK20
(also known as cell cycle-related kinase, CCRK), was identified as
a promising drug target for hepatocellular carcinoma by the PandaOmics<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> software. The absence of structural information
for both protein and reported tool compounds makes CDK20 an ideal
candidate for the validation of our AlphaFold2+Chemistry42 approach.
The CDK20 AlphaFold2 model (AF-Q8IZL9-F1-model_v1) was used as input
for Chemistry42 in the SBDD mode to produce new molecular structures
that would inhibit CDK20. The <italic>Pocket Scanner Module</italic> mapped the ATP-binding site as an ideal pocket of choice to generate
potential inhibitors. To navigate the generation into the chemical
space common for kinases and specifically CDK inhibitors a classic
hinge binder pharmacophore and a SOM trained on the known CDK inhibitors
were used. The <italic>Novelty</italic> filter was engaged to ensure
that generated molecules will not share similar structures to the
existing molecules from the CDK subset of the <italic>HAM data set</italic>. Also <italic>Shape</italic> and <italic>3D-descriptors</italic> modules were disabled at the first de novo stage, since these modules
are not applicable in the absence of the template ligand, when the
apo-structure of modeled protein is used (see disabled modules at
the <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>). In total,
8918 molecules were designed by the generative pipeline. After molecular
docking and visual pose inspection, 54 molecules with diverse hinge
binder scaffolds were prioritized and seven compounds were nominated
for synthesis based on their scores. Among these compounds, a primary
hit containing a quinazoline ring with <italic>K</italic><sub>d</sub> value of 8.9 ± 1.6 μM in a CDK20 binding assay was discovered.
The experimental details of the assay are available in the section
S6 of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.2c01191/suppl_file/ci2c01191_si_001.pdf">SI</ext-link>. Hit-optimization at the second
stage using the 2D PFs functionality was deployed to maintain the
quinazoline scaffold and explore the <italic>R</italic>-group space
to improve the binding affinity of the identified hit-molecule. From
this hit-optimization generation that exploited the same pharmacophore
from the first round and did not use <italic>SOM scoring</italic>,
six molecules were short-listed for synthesis based on their scores,
and two compounds showed remarkable improvement in potency resulting
in <italic>K</italic><sub>d</sub> values of 210.0 ± 42.4 nM and
375 ± 5 nM, respectively. The default set of <italic>MCFs</italic> and default ranges for <italic>Drug-likeness</italic> related properties
(see section S3 in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.2c01191/suppl_file/ci2c01191_si_001.pdf">SI</ext-link>) were applied for
both generations. Altogether this work demonstrated the synergy between
AI methods supporting target identification (PandaOmics), protein
folding (AlphaFold2), and generative chemistry (Chemistry42) in their
ability to effectively contribute to a digital drug development process
when structural data are limited. The structures of all 7 compounds
selected from the first round, as well as those of optimized hit-compound
and their similarity analysis using ChEMBL tools, are available in
the section S7 of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.2c01191/suppl_file/ci2c01191_si_001.pdf">SI</ext-link>.</p>
    </sec>
  </sec>
  <sec id="sec7">
    <title>Chemistry42 Interoperability</title>
    <p>Chemistry42 is accessible
through a web interface built on top
of a distributed cloud platform with scalable cloud architecture.
The implementation integrates a variety of features aimed at optimizing
performance, including cluster management with Kubernetes, multiple
flexible workflows, and integrated monitoring and logging. The structure
and interoperability of the Chemistry42 platform allow its deployment
on either the AWS or Azure cloud or as a SaaS solution (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://chemistry42.com">chemistry42.com</uri>). For either deployment
scenario, the platform can be integrated into already established
workflows.</p>
    <p>Chemistry42 can be connected to Insilico Medicine’s
bioinformatics
web service PandaOmics (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pandaomics.com">https://pandaomics.com</uri>) (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>). PandaOmics
is a comprehensive computational suite for the analysis of -omics
data that provides access to information ranging from disease signatures
to prospective targets and existing drugs. PandaOmics combines classic
bioinformatics methods with signaling pathway analysis using the iPANDA
algorithm.<sup><xref ref-type="bibr" rid="ref29">29</xref>−<xref ref-type="bibr" rid="ref33">33</xref></sup> PandaOmics also provides access to an AI-powered toolkit including
deep feature selection for pathway reconstruction, a pathway scoring
engine, causal inference, a deep-learned transcriptional response
scoring engine, and an activation-based scoring engine. This multimodal
approach combines big data, chemistry, biology, and medicine and allows
a complete characterization of the interplay between molecular structures,
properties, alteration in biological samples, and drug response required
for target discovery.</p>
    <fig id="fig4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>PandaOmics and Chemistry42 platforms integrated into your
drug
discovery pipeline. The interoperability of these platforms allows
an efficient interaction between target identification and de novo
small molecule generation.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci2c01191_0004" id="gr4" position="float"/>
    </fig>
  </sec>
  <sec id="sec8">
    <title>Conclusion</title>
    <p>The Chemistry42 platform (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://chemistry42.com">https://chemistry42.com</uri>) is a
customizable working environment that offers state-of-the-art
AI technologies developed for <italic>de novo</italic> molecular design.
The flexible, user-friendly interface makes Chemistry42 accessible
to medicinal and computational chemists, AI experts, and other scientists
working in the field of drug discovery. The collaborative nature of
Chemistry42 enables and fosters relationships between different scientific
communities and facilitates the decision-making process—a process
which is exceptionally demanding in the field of drug design.</p>
  </sec>
</body>
<back>
  <notes notes-type="data-availability" id="notes-2">
    <title>Data Availability Statement</title>
    <p>The Chemistry42
platform is commercially available to the public (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://chemistry42.com">https://chemistry42.com</uri>). Parts
of the platform, such as the GENTRL algorithm, are available online <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/insilicomedicine/GENTRL">https://github.com/insilicomedicine/GENTRL</uri>. Data for training the models is constructed from publicly available
sources such as ChEMBL (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/chembl/">https://www.ebi.ac.uk/chembl/</uri>).</p>
  </notes>
  <notes id="notes-1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.2c01191?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.2c01191</ext-link>.<list id="silist" list-type="simple"><list-item><p>Example of autoconfiguration, the list of the most important
scores and rewards for different workflows, the list of reward/scoring
functions, visualization of generative models’ performance
during the generation, CDK20 Human CMGC kinase binding assay protocol,
and similarity analysis using ChEMBL tools (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.2c01191/suppl_file/ci2c01191_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci2c01191_si_001.pdf">
        <caption>
          <p>ci2c01191_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="notes-3">
    <p>The authors
declare the following competing financial interest(s): Y.A.I., D.P.,
D.B., B.Z., V.A., P.K., A.A., F.R., and A.Z. work for Insilico Medicine, a commercial artificial intelligence
company that developed the Chemistry42 platform.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>The authors gratefully acknowledge the
valuable comments and
suggestions made by Dr. Jiye Shi from UCB Pharma (Slough, UK).</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Engkvist</surname><given-names>O.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Olivecrona</surname><given-names>M.</given-names></name>; <name><surname>Blaschke</surname><given-names>T.</given-names></name><article-title>The Rise of Deep Learning in Drug Discovery</article-title>. <source>Drug Discovery Today</source><year>2018</year>, <volume>23</volume> (<issue>6</issue>), <fpage>1241</fpage>–<lpage>1250</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2018.01.039</pub-id>.<pub-id pub-id-type="pmid">29366762</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Vanhaelen</surname><given-names>Q.</given-names></name>; <name><surname>Lin</surname><given-names>Y.-C.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><article-title>The Advent
of Generative Chemistry</article-title>. <source>ACS Med. Chem. Lett.</source><year>2020</year>, <volume>11</volume>, <fpage>1496</fpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.0c00088</pub-id>.<pub-id pub-id-type="pmid">32832015</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Yang</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Byrne</surname><given-names>R.</given-names></name>; <name><surname>Schneider</surname><given-names>G.</given-names></name>; <name><surname>Yang</surname><given-names>S.</given-names></name><article-title>Concepts of Artificial Intelligence
for Computer-Assisted Drug Discovery</article-title>. <source>Chem.
Rev.</source><year>2019</year>, <volume>119</volume> (<issue>18</issue>), <fpage>10520</fpage>–<lpage>10594</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00728</pub-id>.<pub-id pub-id-type="pmid">31294972</pub-id></mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Kadurin</surname><given-names>A.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Kazennov</surname><given-names>A.</given-names></name>; <name><surname>Mamoshina</surname><given-names>P.</given-names></name>; <name><surname>Vanhaelen</surname><given-names>Q.</given-names></name>; <name><surname>Khrabrov</surname><given-names>K.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><article-title>The Cornucopia
of Meaningful Leads: Applying Deep Adversarial Autoencoders for New
Molecule Development in Oncology</article-title>. <source>Oncotarget</source><year>2017</year>, <volume>8</volume> (<issue>7</issue>), <fpage>10883</fpage>–<lpage>10890</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.14073</pub-id>.<pub-id pub-id-type="pmid">28029644</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Zhavoronkov</surname><given-names>A.</given-names></name>; <name><surname>Ivanenkov</surname><given-names>Y. A.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Veselov</surname><given-names>M. S.</given-names></name>; <name><surname>Aladinskiy</surname><given-names>V. A.</given-names></name>; <name><surname>Aladinskaya</surname><given-names>A. V.</given-names></name>; <name><surname>Terentiev</surname><given-names>V. A.</given-names></name>; <name><surname>Polykovskiy</surname><given-names>D. A.</given-names></name>; <name><surname>Kuznetsov</surname><given-names>M. D.</given-names></name>; <name><surname>Asadulaev</surname><given-names>A.</given-names></name>; <name><surname>Volkov</surname><given-names>Y.</given-names></name>; <name><surname>Zholus</surname><given-names>A.</given-names></name>; <name><surname>Shayakhmetov</surname><given-names>R. R.</given-names></name>; <name><surname>Zhebrak</surname><given-names>A.</given-names></name>; <name><surname>Minaeva</surname><given-names>L. I.</given-names></name>; <name><surname>Zagribelnyy</surname><given-names>B. A.</given-names></name>; <name><surname>Lee</surname><given-names>L. H.</given-names></name>; <name><surname>Soll</surname><given-names>R.</given-names></name>; <name><surname>Madge</surname><given-names>D.</given-names></name>; <name><surname>Xing</surname><given-names>L.</given-names></name>; <name><surname>Guo</surname><given-names>T.</given-names></name>; <name><surname>Aspuru-Guzik</surname><given-names>A.</given-names></name><article-title>Deep Learning Enables Rapid Identification of Potent
DDR1 Kinase Inhibitors</article-title>. <source>Nat. Biotechnol.</source><year>2019</year>, <volume>37</volume> (<issue>9</issue>), <fpage>1038</fpage>–<lpage>1040</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-019-0224-x</pub-id>.<pub-id pub-id-type="pmid">31477924</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Engkvist</surname><given-names>O.</given-names></name><article-title>Has Drug Design
Augmented by Artificial Intelligence
Become a Reality?</article-title>. <source>Trends Pharmacol. Sci.</source><year>2019</year>, <volume>40</volume> (<issue>11</issue>), <fpage>806</fpage>–<lpage>809</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2019.09.004</pub-id>.<pub-id pub-id-type="pmid">31629547</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Schneider</surname><given-names>G.</given-names></name><article-title>Generative
Models for Artificially-Intelligent Molecular Design</article-title>. <source>Mol. Inform.</source><year>2018</year>, <volume>37</volume> (<issue>1–2</issue>), <fpage>1880131</fpage><pub-id pub-id-type="doi">10.1002/minf.201880131</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Merk</surname><given-names>D.</given-names></name>; <name><surname>Friedrich</surname><given-names>L.</given-names></name>; <name><surname>Grisoni</surname><given-names>F.</given-names></name>; <name><surname>Schneider</surname><given-names>G.</given-names></name><article-title>De Novo Design
of Bioactive Small Molecules by Artificial Intelligence</article-title>. <source>Mol. Inform.</source><year>2018</year>, <volume>37</volume> (<issue>1–2</issue>), <fpage>1700153</fpage><pub-id pub-id-type="doi">10.1002/minf.201700153</pub-id>.<pub-id pub-id-type="pmid">29319225</pub-id></mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="book" id="cit9"><person-group person-group-type="allauthors"><name><surname>Zhavoronkov</surname><given-names>A.</given-names></name></person-group><article-title>From
Paper to Industrial-scale Platform: a 3-Year Behind the Paper Journey
from GENTRL to Chemistry42</article-title>. <source>Bioengeering</source>, <publisher-name>Springer Nature</publisher-name>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bioengineeringcommunity.nature.com/posts/from-paper-to-industrial-scale-platform-a-3-year-behind-the-paper-journey-from-gentrl-to-chemistry42">http://bioengineeringcommunity.nature.com/posts/from-paper-to-industrial-scale-platform-a-3-year-behind-the-paper-journey-from-gentrl-to-chemistry42</uri> (accessed <year>2022</year>-09-21).</mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Polykovskiy</surname><given-names>D.</given-names></name>; <name><surname>Zhebrak</surname><given-names>A.</given-names></name>; <name><surname>Vetrov</surname><given-names>D.</given-names></name>; <name><surname>Ivanenkov</surname><given-names>Y.</given-names></name>; <name><surname>Aladinskiy</surname><given-names>V.</given-names></name>; <name><surname>Mamoshina</surname><given-names>P.</given-names></name>; <name><surname>Bozdaganyan</surname><given-names>M.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name>; <name><surname>Kadurin</surname><given-names>A.</given-names></name><article-title>Entangled Conditional
Adversarial Autoencoder for de Novo Drug Discovery</article-title>. <source>Mol. Pharmaceutics</source><year>2018</year>, <volume>15</volume> (<issue>10</issue>), <fpage>4398</fpage>–<lpage>4405</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00839</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Kadurin</surname><given-names>A.</given-names></name>; <name><surname>Nikolenko</surname><given-names>S.</given-names></name>; <name><surname>Khrabrov</surname><given-names>K.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><article-title>druGAN: An
Advanced Generative Adversarial Autoencoder Model for de Novo Generation
of New Molecules with Desired Molecular Properties in Silico</article-title>. <source>Mol. Pharmaceutics</source><year>2017</year>, <volume>14</volume> (<issue>9</issue>), <fpage>3098</fpage>–<lpage>3104</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00346</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Putin</surname><given-names>E.</given-names></name>; <name><surname>Asadulaev</surname><given-names>A.</given-names></name>; <name><surname>Ivanenkov</surname><given-names>Y.</given-names></name>; <name><surname>Aladinskiy</surname><given-names>V.</given-names></name>; <name><surname>Sanchez-Lengeling</surname><given-names>B.</given-names></name>; <name><surname>Aspuru-Guzik</surname><given-names>A.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><article-title>Reinforced
Adversarial Neural Computer for de Novo Molecular Design</article-title>. <source>J. Chem. Inf. Model.</source><year>2018</year>, <volume>58</volume> (<issue>6</issue>), <fpage>1194</fpage>–<lpage>1204</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.7b00690</pub-id>.<pub-id pub-id-type="pmid">29762023</pub-id></mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Kuznetsov</surname><given-names>M.</given-names></name>; <name><surname>Polykovskiy</surname><given-names>D.</given-names></name><article-title>MolGrow: A
Graph Normalizing Flow for Hierarchical
Molecular Generation</article-title>. <source>AAAI</source><year>2021</year>, <volume>35</volume> (<issue>9</issue>), <fpage>8226</fpage>–<lpage>8234</lpage>. <pub-id pub-id-type="doi">10.1609/aaai.v35i9.17001</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Devi</surname><given-names>R. V.</given-names></name>; <name><surname>Sathya</surname><given-names>S. S.</given-names></name>; <name><surname>Coumar</surname><given-names>M. S.</given-names></name><article-title>Evolutionary
Algorithms for de Novo
Drug Design – A Survey</article-title>. <source>Appl. Soft Comput.</source><year>2015</year>, <volume>27</volume>, <fpage>543</fpage>–<lpage>552</lpage>. <pub-id pub-id-type="doi">10.1016/j.asoc.2014.09.042</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Segler</surname><given-names>M. H. S.</given-names></name>; <name><surname>Kogej</surname><given-names>T.</given-names></name>; <name><surname>Tyrchan</surname><given-names>C.</given-names></name>; <name><surname>Waller</surname><given-names>M. P.</given-names></name><article-title>Generating Focused
Molecule Libraries for Drug Discovery with Recurrent Neural Networks</article-title>. <source>ACS Cent Sci.</source><year>2018</year>, <volume>4</volume> (<issue>1</issue>), <fpage>120</fpage>–<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.7b00512</pub-id>.<pub-id pub-id-type="pmid">29392184</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Baell</surname><given-names>J. B.</given-names></name>; <name><surname>Holloway</surname><given-names>G. A.</given-names></name><article-title>New Substructure Filters for Removal
of Pan Assay Interference
Compounds (PAINS) from Screening Libraries and for Their Exclusion
in Bioassays</article-title>. <source>J. Med. Chem.</source><year>2010</year>, <volume>53</volume> (<issue>7</issue>), <fpage>2719</fpage>–<lpage>2740</lpage>. <pub-id pub-id-type="doi">10.1021/jm901137j</pub-id>.<pub-id pub-id-type="pmid">20131845</pub-id></mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Ivanenkov</surname><given-names>Y. A.</given-names></name>; <name><surname>Zagribelnyy</surname><given-names>B. A.</given-names></name>; <name><surname>Aladinskiy</surname><given-names>V. A.</given-names></name><article-title>Are We Opening the Door to a New
Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?</article-title>. <source>J. Med. Chem.</source><year>2019</year>, <volume>62</volume> (<issue>22</issue>), <fpage>10026</fpage>–<lpage>10043</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00004</pub-id>.<pub-id pub-id-type="pmid">31188596</pub-id></mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Lipinski</surname><given-names>C. A.</given-names></name>; <name><surname>Lombardo</surname><given-names>F.</given-names></name>; <name><surname>Dominy</surname><given-names>B. W.</given-names></name>; <name><surname>Feeney</surname><given-names>P. J.</given-names></name><article-title>Experimental and
Computational Approaches to Estimate Solubility and Permeability in
Drug Discovery and Development Settings</article-title>. <source>Adv.
Drug Delivery Rev.</source><year>2001</year>, <volume>46</volume> (<issue>1–3</issue>), <fpage>3</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/S0169-409X(00)00129-0</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="patent" id="cit19"><person-group person-group-type="allauthors"><name><surname>Zagribelnyy</surname><given-names>B.</given-names></name>; <name><surname>Putin</surname><given-names>E. O.</given-names></name>; <name><surname>Fedorchenko</surname><given-names>S. A.</given-names></name>; <name><surname>Ivanenkov</surname><given-names>Y. A.</given-names></name>; <name><surname>Zavoronkovs</surname><given-names>A.</given-names></name></person-group><article-title>Retrosynthesis-Related
Synthetic Accessibility</article-title>. Patent <patent>2021229454:A1</patent>, November
18, <year>2021</year>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://patentimages.storage.googleapis.com/cc/f9/aa/90acd239be7c4c/WO2021229454A1.pdf">https://patentimages.storage.googleapis.com/cc/f9/aa/90acd239be7c4c/WO2021229454A1.pdf</uri> (accessed 2022-08-11).</mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="book" id="cit20"><person-group person-group-type="allauthors"><name><surname>Yet</surname><given-names>L.</given-names></name></person-group><source>Privileged Structures
in Drug Discovery: Medicinal Chemistry and Synthesis</source>; Methods
and Principles in Medicinal Chemistry; <publisher-name>John Wiley
&amp; Sons</publisher-name>, <year>2018</year>.</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="book" id="cit21"><person-group person-group-type="allauthors"><name><surname>Kohonen</surname><given-names>T.</given-names></name></person-group><source>Self-Organizing Maps</source>, <edition>3</edition>rd. extended ed.; Springer Series in Information
Sciences; <publisher-name>Springer-Verlag</publisher-name>, <publisher-loc>Berlin, Germany</publisher-loc>, <year>2001</year>; Vol. <volume>30</volume>.</mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Kirchmair</surname><given-names>J.</given-names></name>; <name><surname>Göller</surname><given-names>A. H.</given-names></name>; <name><surname>Lang</surname><given-names>D.</given-names></name>; <name><surname>Kunze</surname><given-names>J.</given-names></name>; <name><surname>Testa</surname><given-names>B.</given-names></name>; <name><surname>Wilson</surname><given-names>I. D.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name>; <name><surname>Schneider</surname><given-names>G.</given-names></name><article-title>Predicting
Drug Metabolism: Experiment And/or Computation?</article-title>. <source>Nat. Rev. Drug Discovery</source><year>2015</year>, <volume>14</volume> (<issue>6</issue>), <fpage>387</fpage>–<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1038/nrd4581</pub-id>.<pub-id pub-id-type="pmid">25907346</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="book" id="cit23"><source>Bioisosteres in Medicinal Chemistry</source>; <person-group person-group-type="editor"><name><surname>Brown</surname><given-names>N.</given-names></name></person-group>, Ed.; Methods and Principles
in Medicinal Chemistry; <publisher-name>John Wiley &amp; Sons</publisher-name>, <year>2012</year>; Vol. <volume>54</volume>.</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Yan</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Zheng</surname><given-names>M.</given-names></name>; <name><surname>Ge</surname><given-names>H.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name><article-title>Enhancing
Molecular Shape Comparison by Weighted Gaussian Functions</article-title>. <source>J. Chem. Inf. Model.</source><year>2013</year>, <volume>53</volume> (<issue>8</issue>), <fpage>1967</fpage>–<lpage>1978</lpage>. <pub-id pub-id-type="doi">10.1021/ci300601q</pub-id>.<pub-id pub-id-type="pmid">23845061</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Han</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Zhao</surname><given-names>Z.</given-names></name>; <name><surname>Nie</surname><given-names>W.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>R.</given-names></name><article-title>PDB-Wide Collection of Binding Data:
Current Status of the PDBbind Database</article-title>. <source>Bioinformatics</source><year>2015</year>, <volume>31</volume> (<issue>3</issue>), <fpage>405</fpage>–<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btu626</pub-id>.<pub-id pub-id-type="pmid">25301850</pub-id></mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Polykovskiy</surname><given-names>D.</given-names></name>; <name><surname>Zhebrak</surname><given-names>A.</given-names></name>; <name><surname>Sanchez-Lengeling</surname><given-names>B.</given-names></name>; <name><surname>Golovanov</surname><given-names>S.</given-names></name>; <name><surname>Tatanov</surname><given-names>O.</given-names></name>; <name><surname>Belyaev</surname><given-names>S.</given-names></name>; <name><surname>Kurbanov</surname><given-names>R.</given-names></name>; <name><surname>Artamonov</surname><given-names>A.</given-names></name>; <name><surname>Aladinskiy</surname><given-names>V.</given-names></name>; <name><surname>Veselov</surname><given-names>M.</given-names></name>; <name><surname>Kadurin</surname><given-names>A.</given-names></name>; <name><surname>Johansson</surname><given-names>S.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Nikolenko</surname><given-names>S.</given-names></name>; <name><surname>Aspuru-Guzik</surname><given-names>A.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><article-title>Molecular Sets (MOSES): A Benchmarking Platform for
Molecular Generation Models</article-title>. <source>Front. Pharmacol.</source><year>2020</year>, <volume>11</volume>, <fpage>1931</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.565644</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Jumper</surname><given-names>J.</given-names></name>; <name><surname>Evans</surname><given-names>R.</given-names></name>; <name><surname>Pritzel</surname><given-names>A.</given-names></name>; <name><surname>Green</surname><given-names>T.</given-names></name>; <name><surname>Figurnov</surname><given-names>M.</given-names></name>; <name><surname>Ronneberger</surname><given-names>O.</given-names></name>; <name><surname>Tunyasuvunakool</surname><given-names>K.</given-names></name>; <name><surname>Bates</surname><given-names>R.</given-names></name>; <name><surname>Žídek</surname><given-names>A.</given-names></name>; <name><surname>Potapenko</surname><given-names>A.</given-names></name>; <name><surname>Bridgland</surname><given-names>A.</given-names></name>; <name><surname>Meyer</surname><given-names>C.</given-names></name>; <name><surname>Kohl</surname><given-names>S. A. A.</given-names></name>; <name><surname>Ballard</surname><given-names>A. J.</given-names></name>; <name><surname>Cowie</surname><given-names>A.</given-names></name>; <name><surname>Romera-Paredes</surname><given-names>B.</given-names></name>; <name><surname>Nikolov</surname><given-names>S.</given-names></name>; <name><surname>Jain</surname><given-names>R.</given-names></name>; <name><surname>Adler</surname><given-names>J.</given-names></name>; <name><surname>Back</surname><given-names>T.</given-names></name>; <name><surname>Petersen</surname><given-names>S.</given-names></name>; <name><surname>Reiman</surname><given-names>D.</given-names></name>; <name><surname>Clancy</surname><given-names>E.</given-names></name>; <name><surname>Zielinski</surname><given-names>M.</given-names></name>; <name><surname>Steinegger</surname><given-names>M.</given-names></name>; <name><surname>Pacholska</surname><given-names>M.</given-names></name>; <name><surname>Berghammer</surname><given-names>T.</given-names></name>; <name><surname>Bodenstein</surname><given-names>S.</given-names></name>; <name><surname>Silver</surname><given-names>D.</given-names></name>; <name><surname>Vinyals</surname><given-names>O.</given-names></name>; <name><surname>Senior</surname><given-names>A. W.</given-names></name>; <name><surname>Kavukcuoglu</surname><given-names>K.</given-names></name>; <name><surname>Kohli</surname><given-names>P.</given-names></name>; <name><surname>Hassabis</surname><given-names>D.</given-names></name><article-title>Highly Accurate Protein
Structure Prediction with AlphaFold</article-title>. <source>Nature</source><year>2021</year>, <volume>596</volume> (<issue>7873</issue>), <fpage>583</fpage>–<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id>.<pub-id pub-id-type="pmid">34265844</pub-id></mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Ren</surname><given-names>F.</given-names></name>; <name><surname>Ding</surname><given-names>X.</given-names></name>; <name><surname>Zheng</surname><given-names>M.</given-names></name>; <name><surname>Korzinkin</surname><given-names>M.</given-names></name>; <name><surname>Cai</surname><given-names>X.</given-names></name>; <name><surname>Zhu</surname><given-names>W.</given-names></name>; <name><surname>Mantsyzov</surname><given-names>A.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Aladinskiy</surname><given-names>V.</given-names></name>; <name><surname>Cao</surname><given-names>Z.</given-names></name>; <name><surname>Kong</surname><given-names>S.</given-names></name>; <name><surname>Long</surname><given-names>X.</given-names></name>; <name><surname>Man Liu</surname><given-names>B. H.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Naumov</surname><given-names>V.</given-names></name>; <name><surname>Shneyderman</surname><given-names>A.</given-names></name>; <name><surname>Ozerov</surname><given-names>I. V.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Pun</surname><given-names>F. W.</given-names></name>; <name><surname>Polykovskiy</surname><given-names>D. A.</given-names></name>; <name><surname>Sun</surname><given-names>C.</given-names></name>; <name><surname>Levitt</surname><given-names>M.</given-names></name>; <name><surname>Aspuru-Guzik</surname><given-names>A.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><article-title>AlphaFold Accelerates Artificial
Intelligence Powered Drug Discovery: Efficient Discovery of a Novel
CDK20 Small Molecule Inhibitor</article-title>. <source>Chem. Sci.</source><year>2023</year>, <pub-id pub-id-type="doi">10.1039/D2SC05709C</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Ozerov</surname><given-names>I.
V.</given-names></name>; <name><surname>Lezhnina</surname><given-names>K. V.</given-names></name>; <name><surname>Izumchenko</surname><given-names>E.</given-names></name>; <name><surname>Artemov</surname><given-names>A. V.</given-names></name>; <name><surname>Medintsev</surname><given-names>S.</given-names></name>; <name><surname>Vanhaelen</surname><given-names>Q.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Vijg</surname><given-names>J.</given-names></name>; <name><surname>Osipov</surname><given-names>A. N.</given-names></name>; <name><surname>Labat</surname><given-names>I.</given-names></name>; <name><surname>West</surname><given-names>M. D.</given-names></name>; <name><surname>Buzdin</surname><given-names>A.</given-names></name>; <name><surname>Cantor</surname><given-names>C. R.</given-names></name>; <name><surname>Nikolsky</surname><given-names>Y.</given-names></name>; <name><surname>Borisov</surname><given-names>N.</given-names></name>; <name><surname>Irincheeva</surname><given-names>I.</given-names></name>; <name><surname>Khokhlovich</surname><given-names>E.</given-names></name>; <name><surname>Sidransky</surname><given-names>D.</given-names></name>; <name><surname>Camargo</surname><given-names>M. L.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><article-title>In Silico
Pathway Activation Network Decomposition Analysis (iPANDA) as a Method
for Biomarker Development</article-title>. <source>Nat. Commun.</source><year>2016</year>, <volume>7</volume>, <fpage>13427</fpage><pub-id pub-id-type="doi">10.1038/ncomms13427</pub-id>.<pub-id pub-id-type="pmid">27848968</pub-id></mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Stamatas</surname><given-names>G. N.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Pappas</surname><given-names>A.</given-names></name>; <name><surname>Mirmirani</surname><given-names>P.</given-names></name>; <name><surname>McCormick</surname><given-names>T. S.</given-names></name>; <name><surname>Cooper</surname><given-names>K. D.</given-names></name>; <name><surname>Consolo</surname><given-names>M.</given-names></name>; <name><surname>Schastnaya</surname><given-names>J.</given-names></name>; <name><surname>Ozerov</surname><given-names>I. V.</given-names></name>; <name><surname>Aliper</surname><given-names>A.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><article-title>An Analysis
of Gene Expression Data Involving Examination of Signaling Pathways
Activation Reveals New Insights into the Mechanism of Action of Minoxidil
Topical Foam in Men with Androgenetic Alopecia</article-title>. <source>Cell Cycle</source><year>2017</year>, <volume>16</volume> (<issue>17</issue>), <fpage>1578</fpage>–<lpage>1584</lpage>. <pub-id pub-id-type="doi">10.1080/15384101.2017.1327492</pub-id>.<pub-id pub-id-type="pmid">28594262</pub-id></mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="journal" id="cit31"><name><surname>Ravi</surname><given-names>R.</given-names></name>; <name><surname>Noonan</surname><given-names>K. A.</given-names></name>; <name><surname>Pham</surname><given-names>V.</given-names></name>; <name><surname>Bedi</surname><given-names>R.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name>; <name><surname>Ozerov</surname><given-names>I. V.</given-names></name>; <name><surname>Makarev</surname><given-names>E.</given-names></name>; <name><surname>V. Artemov</surname><given-names>A.</given-names></name>; <name><surname>Wysocki</surname><given-names>P. T.</given-names></name>; <name><surname>Mehra</surname><given-names>R.</given-names></name>; <name><surname>Nimmagadda</surname><given-names>S.</given-names></name>; <name><surname>Marchionni</surname><given-names>L.</given-names></name>; <name><surname>Sidransky</surname><given-names>D.</given-names></name>; <name><surname>Borrello</surname><given-names>I. M.</given-names></name>; <name><surname>Izumchenko</surname><given-names>E.</given-names></name>; <name><surname>Bedi</surname><given-names>A.</given-names></name><article-title>Bifunctional Immune Checkpoint-Targeted Antibody-Ligand Traps That
Simultaneously Disable TGFβ Enhance the Efficacy of Cancer Immunotherapy</article-title>. <source>Nat. Commun.</source><year>2018</year>, <volume>9</volume> (<issue>1</issue>), <fpage>741</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-02696-6</pub-id>.<pub-id pub-id-type="pmid">29467463</pub-id></mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Saloura</surname><given-names>V.</given-names></name>; <name><surname>Izumchenko</surname><given-names>E.</given-names></name>; <name><surname>Zuo</surname><given-names>Z.</given-names></name>; <name><surname>Bao</surname><given-names>R.</given-names></name>; <name><surname>Korzinkin</surname><given-names>M.</given-names></name>; <name><surname>Ozerov</surname><given-names>I.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name>; <name><surname>Sidransky</surname><given-names>D.</given-names></name>; <name><surname>Bedi</surname><given-names>A.</given-names></name>; <name><surname>Hoque</surname><given-names>M. O.</given-names></name>; <name><surname>Koeppen</surname><given-names>H.</given-names></name>; <name><surname>Keck</surname><given-names>M. K.</given-names></name>; <name><surname>Khattri</surname><given-names>A.</given-names></name>; <name><surname>London</surname><given-names>N.</given-names></name>; <name><surname>Kotlov</surname><given-names>N.</given-names></name>; <name><surname>Fatima</surname><given-names>A.</given-names></name>; <name><surname>Vougiouklakis</surname><given-names>T.</given-names></name>; <name><surname>Nakamura</surname><given-names>Y.</given-names></name>; <name><surname>Lingen</surname><given-names>M.</given-names></name>; <name><surname>Agrawal</surname><given-names>N.</given-names></name>; <name><surname>Savage</surname><given-names>P. A.</given-names></name>; <name><surname>Kron</surname><given-names>S.</given-names></name>; <name><surname>Kline</surname><given-names>J.</given-names></name>; <name><surname>Kowanetz</surname><given-names>M.</given-names></name>; <name><surname>Seiwert</surname><given-names>T. Y.</given-names></name><article-title>Immune Profiles in Primary Squamous
Cell Carcinoma
of the Head and Neck</article-title>. <source>Oral Oncol.</source><year>2019</year>, <volume>96</volume>, <fpage>77</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.oraloncology.2019.06.032</pub-id>.<pub-id pub-id-type="pmid">31422218</pub-id></mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Subbannayya</surname><given-names>T.</given-names></name>; <name><surname>Leal-Rojas</surname><given-names>P.</given-names></name>; <name><surname>Zhavoronkov</surname><given-names>A.</given-names></name>; <name><surname>Ozerov</surname><given-names>I. V.</given-names></name>; <name><surname>Korzinkin</surname><given-names>M.</given-names></name>; <name><surname>Babu</surname><given-names>N.</given-names></name>; <name><surname>Radhakrishnan</surname><given-names>A.</given-names></name>; <name><surname>Chavan</surname><given-names>S.</given-names></name>; <name><surname>Raja</surname><given-names>R.</given-names></name>; <name><surname>Pinto</surname><given-names>S. M.</given-names></name>; <name><surname>Patil</surname><given-names>A. H.</given-names></name>; <name><surname>Barbhuiya</surname><given-names>M. A.</given-names></name>; <name><surname>Kumar</surname><given-names>P.</given-names></name>; <name><surname>Guerrero-Preston</surname><given-names>R.</given-names></name>; <name><surname>Navani</surname><given-names>S.</given-names></name>; <name><surname>Tiwari</surname><given-names>P. K.</given-names></name>; <name><surname>Kumar</surname><given-names>R. V.</given-names></name>; <name><surname>Prasad</surname><given-names>T. S. K.</given-names></name>; <name><surname>Roa</surname><given-names>J. C.</given-names></name>; <name><surname>Pandey</surname><given-names>A.</given-names></name>; <name><surname>Sidransky</surname><given-names>D.</given-names></name>; <name><surname>Gowda</surname><given-names>H.</given-names></name>; <name><surname>Izumchenko</surname><given-names>E.</given-names></name>; <name><surname>Chatterjee</surname><given-names>A.</given-names></name><article-title>PIM1 Kinase Promotes Gallbladder Cancer Cell Proliferation
via Inhibition of Proline-Rich Akt Substrate of 40 kDa (PRAS40)</article-title>. <source>J. Cell Commun. Signal.</source><year>2019</year>, <volume>13</volume> (<issue>2</issue>), <fpage>163</fpage>–<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1007/s12079-018-00503-5</pub-id>.<pub-id pub-id-type="pmid">30666556</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
